Homotryptamines as potent and selective serotonin reuptake inhibitors (SSRIs)

Bioorganic and Medicinal Chemistry Letters

Volumn 15, Issue 6, 2005, Pages 1619-1621

  Schmitz, William D ^a   Denhart, Derek J ^a   Brenner, Allison B ^a   Ditta, Jonathan L ^a   Mattson, Ronald J ^a   Mattson, Gail K ^a   Molski, Thaddeus F ^a   Macor, John E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Homotryptamines; Serotonin reuptake; SSRI

Indexed keywords

SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; TRYPTAMINE DERIVATIVE;

ARTICLE; CONFORMATION; CONTROLLED STUDY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ELECTRON TRANSPORT; EMBRYO; HUMAN; HUMAN CELL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

EID: 14644432981     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.01.059     Document Type: Article

References (24)

1. M. Vaswani, F.K. Linda, and S. Ramesh Prog. Neuro-Psycopha. 27 2003 85 102
2. D. Spinks, and G. Spinks Curr. Med. Chem. 9 2002 799 810
3. S.H. Preskorn, R. Ross, and C.Y. Stanga S.H. Preskorn J.P. Feighner C.Y. Stanga Antidepressants: Past, Present and Future 2004 Springer Berlin 241 262
4. G.B. Baker, J. Fang, S. Sinha, and R.T. Coutts Neurosci. Biobehav. R. 22 1998 325 333
5. A.S. Horn J. Neurochem. 21 1973 883 888
6. E.M. Adkins, E.L. Barker, and R.D. Blakely Mol. Pharmacol. 59 2001 514 523
7. Cipollina, J. A., Mattson, R. J., Sloan, C. P. U.S. Patent 5468767, 1995
8. T. Heinrich, H. Böttcher, R. Gericke, G.D. Bartoszyk, S. Anzali, C.A. Seyfried, H.E. Greiner, and C. van Amsterdam J. Med. Chem. 47 2004 4684 4692
9. Audia, J. E., Koch, D. J., Mabry, T. E., Rocco, V., P., Xu, Y-C. U.S. Patent 5846982, 1998
10. K.L. Meagher, R.E. Mewshaw, D.A. Evrard, P. Zhou, D.L. Smith, R. Scerni, T. Spangler, S. Abulhawa, X. Shi, L.E. Schechter, and T.H. Andree Bioorg. Med. Chem. Lett. 11 2001 1885 1888
11. R.E. Mewshaw, D. Zhou, P. Zhou, X. Shi, G. Hornby, T. Spangler, R. Scerni, D. Smith, L.E. Schechter, and T.H. Andree J. Med. Chem. 47 2004 3823 3842
12. 1A modulators, see: R.A. Glennon Drug Dev. Res. 26 1992 251 274
13. R.M. Pinder, D.M. Green, K. Brewster, and P.B.J. Thompson J. Pharm. Pharmacol. 25 1973 847 848
14. 6 binding R.A. Glennon, M. Bondarev, and B. Roth Med. Chem. Res. 9 2 1999 108 117
15. M. Dukat, C. Smith, K. Herrick-Davis, M. Teitler, and R.A. Glennon Bioorg. Med. Chem. 12 2004 2545 2552
16. D.J. Denhart, R.J. Mattson, J.L. Ditta, and J.E. Macor Tetrahedron Lett. 45 2004 3803 3805
17. J.E. Macor, D.H. Blank, R.J. Post, and K. Ryan Tetrahedron Lett. 33 1992 8011 8014
18. F.J. Ricciardi, and P.H. Doukas Heterocycles 24 1986 971 977
19. Percent inhibition at both norepinephrine and dopamine transporters was found to be <50% at a concentration of 1 μM for all active (<1000 nM) SERT compounds listed in Table 1. The most potent compounds exhibited the best selectivity; for example, 2J showed 14% inhibition at the norepinephrine transporter and 4% at the dopamine transporter at 1 μM
20. J.E. Macor, J. Blake, C.B. Fox, C. Johnson, B.K. Koe, L.A. Lebel, J.M. Morrone, K. Ryan, A.W. Schmidt, D.W. Schulz, and S.H. Zorn J. Med. Chem. 35 1992 4503 4505
21. J.E. Macor, C.B. Fox, C. Johnson, B.K. Koe, L.A. Lebel, and S.H. Zorn J. Med. Chem. 35 1992 3625 3632
22. L. Matzen, C. Amsterdam, W. Rautenberg, H.E. Greiner, J. Harting, C.A. Seyfried, and H. Bottcher J. Med. Chem. 43 2000 1149 1157
23. K.M. Boy, M. Dee, J. Yevich, J. Torrente, Q. Gao, L. Iben, A. Stark, and R.J. Mattson Bioorg. Med. Chem. Lett. 14 2004 4467 4470
24. N. Toda, K. Tago, S. Marumoto, K. Takami, M. Ori, N. Yamada, K. Koyama, S. Naruto, K. Abe, R. Yamazaki, T. Hara, A. Aoyagi, Y. Abe, T. Kaneko, and H. Kogen Bioorg. Med. Chem. 11 2003 4389 4415